Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Phase II Study Using Thalidomide for the Treatment of ALS
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-11-21
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT00140452
- Locations
- 🇺🇸
Dartmouth Hichcock Medical Center, Lebanon, New Hampshire, United States
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 7
- Registration Number
- NCT00124579
- Locations
- 🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸St. James Healthcare Cancer Care, Butte, Montana, United States
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- University Hospital, Bonn
- Target Recruit Count
- 80
- Registration Number
- NCT00124813
- Locations
- 🇩🇪
Medical Clinic & Policlinic III, University of Bonn, Bonn, Germany
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2010-02-01
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 37
- Registration Number
- NCT00114192
- Locations
- 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- The Cleveland Clinic
- Registration Number
- NCT00112879
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 178
- Registration Number
- NCT00112502
- Locations
- 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 64
- Registration Number
- NCT00104988
- Locations
- 🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸U.T. Cancer Institute at University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸Cottonwood Hospital Medical Center, Murray, Utah, United States
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00098865
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 452
- Registration Number
- NCT00098475
- Locations
- 🇺🇸
OSF Saint Anthony's Health Center, Alton, Illinois, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Huntsville Hospital, Huntsville, Alabama, United States
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2017-04-07
- Target Recruit Count
- 225
- Registration Number
- NCT00097981
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.